Abstract： Objective： To observe the clinical effect of modified Shashen Maidong Decoction combined with sequential therapy of Azithromycin on mycoplasma pneumonia (MMP) in children. Methods： A total of 80 children with MPP were divided into the conventional group and the trial group by random number table method， with 40 cases in each group. The conventional group was given sequential therapy of Azithromycin，and the trial group was given modified Shashen Maidong Decoction combined with sequential therapy of azithromycin. Ten days after treatment， the clinical effects， the remission time of symptoms and signs and the incidence of adverse reactions were compared between the two groups. The traditional Chinese medicine (TCM) syndrome scores and levels of inflammatory factors， including interleukin- 6 (IL- 6)， tumor necrosis factor- α (TNF- α) and procalcitonin (PCT) were compared before and after treatment between the two groups. Results： The total effective rate was 97.50% in the trial group and 80.00% in the conventional group， the difference being significant (P＜ 0.05). After treatment，the disappearing time of fever，asthma，cough and rales in the trial group was respectively shorter than that in the conventional group，the difference being significant (P＜0.05). After treatment，the main and secondary syndrome scores and total scores in the two groups were decreased when compared with those before treatment (P＜0.05)， and the above scores in the trial group were lower than those in the conventional group (P＜0.05). After treatment，the levels of IL- 6，TNF- α and PCT in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above levels in the trial group were lower than those in the conventional group (P＜0.05). During treatment， the incidence of adverse reactions was 15.00% in the trial group and 17.50% in the conventional group， there being no significant difference between the two groups (P＞0.05). Conclusion： Modified Shashen Maidong Decoction combined with sequential therapy of Azithromycin can improve the clinical effect， reduce the levels of inflammatory factors， and effectively relieve the symptoms and signs of children with MPP.